Indivior PLC announced that the FDA has approved Sublocade (buprenorphine extended- release) injection for subcutaneous use (CIII).
Indivior announced the publication of patient-centered outcome endpoints (health status, physical and mental health, medication satisfaction, employment, health insurance status...
Indivior has announced new data from the two-year phase III analysis of the 24-month real-world observational study, RECOVER in individuals with moderate to severe opioid use disorder (OUD) following their transition from two Phase III clinical trials of Sublocade (buprenorphine extended-release) injection, for subcutaneous use (CIII) into a real-world setting.